





- Co-registration
- Percutaneous Coronary Interventions (PCI)
- Coronary Physiology
- Instantaneous wave-Free Ratio (iFR)
Core Essentials of Understanding Co-Registration
Simple Education, is a leading provider of coronary physiology and intracoronary imaging courses to aid treatment of complex coronary artery disease.
Speakers
Dr Justin Davies is a board member of Monaco Cardio at the Princess Grace Hospital, Monaco, and... Dr Justin Davies is a board member of Monaco Cardio at the Princess Grace Hospital, Monaco, and an interventional cardiologist with over 15 years of experience as a leading educator in the field. His clinical and academic career was established at Hammersmith Hospital, Imperial College London, where he built an international reputation for innovation in cardiovascular medicine. Over the course of his career, he has successfully mentored 15 PhD students, published more than 500 peer-reviewed papers — including landmark studies in the New England Journal of Medicine and The Lancet — and holds 20 patents in cardiovascular medicine and technology. He was the co-principal investigator of the DEFINE-FLAIR study, which helped establish iFR (Instantaneous Wave-Free Ratio), a diagnostic technique he invented, as a globally adopted standard in coronary physiology. His work reflects a unique blend of scientific innovation, academic leadership, and clinical excellence. In addition to his research and academic commitments, Justin is CEO of Cerebria AI, where he leads the development of next-generation AI-powered cardiovascular imaging and physiology tools. Under his leadership, Cerebria AI is advancing cutting-edge solutions that integrate artificial intelligence with frontline cardiology to enhance clinical decision-making and patient outcomes. Combining deep clinical expertise with entrepreneurial vision, he continues to guide international ventures through funding, regulatory pathways, and commercialization, while remaining committed to transforming cardiovascular care on a global scale.
Carlo Di Mario is Professor of Cardiology at the University of Florence and Director of the... Carlo Di Mario is Professor of Cardiology at the University of Florence and Director of the Structural Interventional Cardiology Division of the University Hospital Careggi, Florence, Italy. Previous posts included 15 years as Professor of Clinical Cardiology at Imperial College of Sciences, Medicine & Technology, London and Consultant Cardiologist at the Royal Brompton Hospital. Despite his teaching, research and administrative commitments, he maintains an active clinical involvement performing more than 100 PCI per year with special interest in the treatment of calcified lesions, chronic total occlusions, bifurcations, and diffuse disease. He is a regular TAVI operator and certified implanter for the Medtronic Evolut R and Edwards Sapien 3 transcatheter aortic valves. He participated in more than 160 MitraClip implantations in London and Florence and has recently started direct annuloplasty with the CardioBand. Professor Di Mario pioneered the use of intracoronary Doppler, pressure measurement, intravascular ultrasound, optical coherence tomography, and near infrared spectroscopy. He was PI of the OPTICUS trial, failing to demonstrate superiority of IVUS guided stenting, and of the Lipid Rich Plaque study, due to report at TCT 2018. He was Principal Investigator of the DESTINI trial, using Doppler CRF to identify lesions in need of stenting, and of the CARESS in AMI trial, a large multicentre trial showing that patients who receive fibrinolytic therapy for ST-elevation myocardial infarction benefit from early angioplasty. This trial and a subsequent meta-analysis have led to a change in the European Society of Cardiology and AHA/ACC Guidelines for treatment of STEMI patients. He cooperated with Dr Davies to the validation of iFR to assess lesion severity and discriminate the contribution of individual lesions, and with Dr Lyon in the intracoronary delivery of SERCA-2 genes via adenoviral vectors in the CUPID2 trial.
Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate... Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory at St. Francis Hospital in Roslyn, New York. He is also a member of the Cardiovascular Research Foundation in New York City where he currently serves as the Director of the Physiology Core Laboratory. He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, and Harvard Medical School. He has been a high volume interventional cardiologist since 2006 and recognized as a Top Doctor in the New York Metro Area by Castle Connolly. Dr. Jeremias has significantly contributed to advancing the field of interventional cardiology and he is considered one of the foremost authorities in coronary physiology and intravascular imaging. He is a co-director of the annual St. Francis Intravascular Imaging and Coronary Physiology Workshop, teaching physicians around the world on “Precision Angioplasty”. Dr. Jeremias is presently engaged in a major global study that could change the path of treating clogged arteries. Known as the ILUMIEN IV trial, this major clinical study is evaluating Optical Coherence Tomography (OCT) to guide coronary stent placement. He is also the principal investigator of DEFINE PCI, an international study on assessing the improvement in blood flow after stent placement for severe coronary blockages.